264 related articles for article (PubMed ID: 29895969)
1. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway.
Chen S; Zhou Q; Guo Z; Wang Y; Wang L; Liu X; Lu M; Ju L; Xiao Y; Wang X
J Cell Mol Med; 2020 Jan; 24(2):1804-1821. PubMed ID: 31821699
[TBL] [Abstract][Full Text] [Related]
3. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V
Gynecol Oncol; 2017 Apr; 145(1):159-166. PubMed ID: 28214016
[TBL] [Abstract][Full Text] [Related]
4. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.
Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E
Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676
[TBL] [Abstract][Full Text] [Related]
5. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma.
Jeddo SFA; Wei X; Li K; Li X; Yang Q; Dongol S; Li J
Oncol Rep; 2020 Sep; 44(3):1037-1048. PubMed ID: 32705239
[TBL] [Abstract][Full Text] [Related]
6. Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma.
Bolomsky A; Heusschen R; Schlangen K; Stangelberger K; Muller J; Schreiner W; Zojer N; Caers J; Ludwig H
Haematologica; 2018 Feb; 103(2):325-335. PubMed ID: 29122991
[TBL] [Abstract][Full Text] [Related]
7. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases.
Ji W; Arnst C; Tipton AR; Bekier ME; Taylor WR; Yen TJ; Liu ST
PLoS One; 2016; 11(4):e0153518. PubMed ID: 27082996
[TBL] [Abstract][Full Text] [Related]
8. Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.
Muller J; Bolomsky A; Dubois S; Duray E; Stangelberger K; Plougonven E; Lejeune M; Léonard A; Marty C; Hempel U; Baron F; Beguin Y; Cohen-Solal M; Ludwig H; Heusschen R; Caers J
Haematologica; 2018 Aug; 103(8):1359-1368. PubMed ID: 29748441
[TBL] [Abstract][Full Text] [Related]
9. A novel carbon-11 radiolabeled maternal embryonic leucine zipper kinase inhibitor for PET imaging of triple-negative breast cancer.
Tang R; Gai Y; Li K; Hu F; Gong C; Wang S; Feng F; Altine B; Hu J; Lan X
Bioorg Chem; 2021 Feb; 107():104609. PubMed ID: 33454507
[TBL] [Abstract][Full Text] [Related]
10. MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways.
Zhang X; Wang J; Wang Y; Liu G; Li H; Yu J; Wu R; Liang J; Yu R; Liu X
Front Oncol; 2020; 10():608082. PubMed ID: 33520717
[TBL] [Abstract][Full Text] [Related]
11. MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway.
Xu Q; Ge Q; Zhou Y; Yang B; Yang Q; Jiang S; Jiang R; Ai Z; Zhang Z; Teng Y
EBioMedicine; 2020 Jan; 51():102609. PubMed ID: 31915116
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells.
McDonald IM; Grant GD; East MP; Gilbert TSK; Wilkerson EM; Goldfarb D; Beri J; Herring LE; Vaziri C; Cook JG; Emanuele MJ; Graves LM
J Biol Chem; 2020 Feb; 295(8):2359-2374. PubMed ID: 31896573
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant.
Simon M; Mesmar F; Helguero L; Williams C
PLoS One; 2017; 12(2):e0172832. PubMed ID: 28235006
[TBL] [Abstract][Full Text] [Related]
14. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
15. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor.
Cho YS; Kang Y; Kim K; Cha YJ; Cho HS
Biochem Biophys Res Commun; 2014 Apr; 447(1):7-11. PubMed ID: 24657156
[TBL] [Abstract][Full Text] [Related]
16. Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma.
Kiseljak-Vassiliades K; Zhang Y; Kar A; Razzaghi R; Xu M; Gowan K; Raeburn CD; Albuja-Cruz M; Jones KL; Somerset H; Fishbein L; Leong S; Wierman ME
Endocrinology; 2018 Jul; 159(7):2532-2544. PubMed ID: 29790920
[TBL] [Abstract][Full Text] [Related]
17. [
Hu F; Gong C; Gai Y; Jiang D; Liu Q; Wang S; Hu M; Pi R; Shu H; Hu J; Lan X
Mol Pharm; 2021 Sep; 18(9):3544-3552. PubMed ID: 34482695
[TBL] [Abstract][Full Text] [Related]
18. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.
Chung S; Suzuki H; Miyamoto T; Takamatsu N; Tatsuguchi A; Ueda K; Kijima K; Nakamura Y; Matsuo Y
Oncotarget; 2012 Dec; 3(12):1629-40. PubMed ID: 23283305
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.
Alachkar H; Mutonga MB; Metzeler KH; Fulton N; Malnassy G; Herold T; Spiekermann K; Bohlander SK; Hiddemann W; Matsuo Y; Stock W; Nakamura Y
Oncotarget; 2014 Dec; 5(23):12371-82. PubMed ID: 25365263
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma.
Cigliano A; Pilo MG; Mela M; Ribback S; Dombrowski F; Pes GM; Cossu A; Evert M; Calvisi DF; Utpatel K
Medicina (Kaunas); 2019 Dec; 56(1):. PubMed ID: 31861475
[No Abstract] [Full Text] [Related]
[Next] [New Search]
